Código QR (código de barras bidimensional)

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

IntroductionHigh-dose interleukin-2 (HD IL-2) and pembrolizumab are each approved as single agents by the U.S. F.D.A. for the treatment of metastatic melanoma. There is limited data using the agents concurrently. The objectives of this study were to characterize the safety profile of IL-2 in combina...

ver descrição completa

Na minha lista:
Principais autores: Ann W. Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P. Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Howard L. Kaufman, Janice M. Mehnert, David F. McDermott
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2023-02-01
coleção:Frontiers in Oncology
Assuntos:
melanoma
interleukin-2
cytokine
pembrolizumab
combination immunotherapy
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fonc.2023.1108341/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados